Crossmark Global Holdings Inc. Raises Holdings in McKesson Corporation $MCK

Crossmark Global Holdings Inc. lifted its holdings in McKesson Corporation (NYSE:MCK) by 22.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,319 shares of the company’s stock after buying an additional 4,513 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in McKesson were worth $18,787,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. IAM Advisory LLC boosted its position in shares of McKesson by 0.3% during the 3rd quarter. IAM Advisory LLC now owns 3,908 shares of the company’s stock worth $3,019,000 after purchasing an additional 13 shares in the last quarter. PDS Planning Inc lifted its stake in shares of McKesson by 1.1% in the third quarter. PDS Planning Inc now owns 1,209 shares of the company’s stock valued at $934,000 after purchasing an additional 13 shares during the period. Berkshire Asset Management LLC PA boosted its holdings in McKesson by 4.6% during the third quarter. Berkshire Asset Management LLC PA now owns 294 shares of the company’s stock worth $227,000 after buying an additional 13 shares in the last quarter. Goldstein Advisors LLC grew its position in McKesson by 4.4% during the third quarter. Goldstein Advisors LLC now owns 334 shares of the company’s stock worth $258,000 after buying an additional 14 shares during the period. Finally, Warren Street Wealth Advisors LLC increased its holdings in McKesson by 4.9% in the third quarter. Warren Street Wealth Advisors LLC now owns 319 shares of the company’s stock valued at $246,000 after buying an additional 15 shares in the last quarter. Hedge funds and other institutional investors own 85.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on MCK. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of McKesson in a research note on Wednesday, December 10th. Mizuho upped their target price on McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a report on Thursday, February 5th. Zacks Research cut McKesson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 25th. Leerink Partners reaffirmed an “outperform” rating and set a $1,085.00 price target on shares of McKesson in a research note on Thursday. Finally, Evercore reissued an “outperform” rating on shares of McKesson in a research note on Thursday. Thirteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $960.93.

McKesson Price Performance

McKesson stock opened at $931.00 on Friday. The stock has a market capitalization of $114.04 billion, a P/E ratio of 26.78, a P/E/G ratio of 1.58 and a beta of 0.38. McKesson Corporation has a 12-month low of $626.33 and a 12-month high of $999.00. The firm’s 50-day moving average is $880.72 and its two-hundred day moving average is $814.03.

McKesson (NYSE:MCK) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, beating analysts’ consensus estimates of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The business had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. During the same quarter in the previous year, the business earned $8.03 earnings per share. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, analysts forecast that McKesson Corporation will post 32.77 EPS for the current year.

McKesson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be given a $0.82 dividend. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. McKesson’s dividend payout ratio (DPR) is currently 9.43%.

Insider Transactions at McKesson

In other news, EVP Leann B. Smith sold 190 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total transaction of $179,550.00. Following the completion of the sale, the executive vice president directly owned 2,989 shares of the company’s stock, valued at $2,824,605. The trade was a 5.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Michele Lau sold 2,725 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $990.00, for a total value of $2,697,750.00. Following the sale, the executive vice president owned 3,247 shares of the company’s stock, valued at approximately $3,214,530. The trade was a 45.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 3,868 shares of company stock valued at $3,743,820 in the last quarter. Insiders own 0.08% of the company’s stock.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.